|
Oct 1
|
Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion
|
|
Jul 30
|
Evoke Pharma, Inc. Announces Reverse Stock Split
|
|
May 16
|
Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference
|
|
May 14
|
Evoke Pharma Reports First Quarter 2024 Financial Results
|
|
Apr 17
|
Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications
|
|
Mar 21
|
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer
|
|
Mar 16
|
Evoke Pharma, Inc. (NASDAQ:EVOK): Are Analysts Optimistic?
|
|
Mar 15
|
Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2023 Earnings Call Transcript
|
|
Mar 15
|
Q4 2023 Evoke Pharma Inc Earnings Call
|
|
Mar 14
|
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 7
|
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024
|
|
Nov 30
|
Revolutionizing gastroparesis treatment: Evoke Pharma's CEO talks game-changing nasal spray
|
|
Nov 27
|
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent
|
|
Aug 10
|
Evoke Pharma Reports Second Quarter 2023 Financial Results
|
|
Aug 7
|
Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting
|